

Regd. Off. : 37, First Floor, Kamala Bhavan II, S. Nityananad Road, Andheri (East), Mumbai - 400 069 Email : gufic@guficbio.com

25/LEGAL/NSE/2013-14/GBSL

15<sup>th</sup> February, 2014

To,  
**National Stock Exchange of India Limited,**  
Exchange Plaza, Bandra – Kurla Complex,  
Bandra (E), Mumbai – 400051

Symbol: **GUFICBIO**

Dear Sir/Madam,

Sub: Outcome of the Board of Directors Meeting


With respect to the captioned matter, this is to inform you that meeting of the Board of Directors of the Company was held today, 15th February, 2014, at 4.30 p.m. at the Registered Office of the Company.

Wherein the Board of Directors, among other items, approved the Unaudited Financial Results for the quarter ended on 31st December, 2013. The copy of the said Results is enclosed herewith.

Kindly do the needful.

Thanking You,

Yours truly,  
For Gufic Biosciences Limited

  
for Prakash G. Khulbe  
Company Secretary & Compliance Officer

**GUFIC BIOSCIENCES LIMITED**

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2013**

|                                                                                         | Rs. in Lacs                              |                                          |                                          |                                          |                                                 |                                                 |                                             |
|-----------------------------------------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------|
| Particulars                                                                             | Quarter Ended<br>31.12.2013<br>Unaudited | Quarter Ended<br>30.09.2013<br>Unaudited | Quarter Ended<br>30.06.2013<br>Unaudited | Quarter Ended<br>31.12.2012<br>Unaudited | For the Period Ended<br>31.12.2013<br>Unaudited | For the Period Ended<br>31.12.2012<br>Unaudited | For the Year Ended<br>31.03.2013<br>Audited |
| <b>INCOME:</b>                                                                          |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| Net Sales / Income from Operations (Net of Excise Duty)                                 | 3130.89                                  | 2901.44                                  | 2536.92                                  | 2461.77                                  | 8569.25                                         | 7546.09                                         | 9998.31                                     |
| Other Operating Income                                                                  | 4.84                                     | 1.89                                     | 2.33                                     | 14.77                                    | 9.06                                            | 28.77                                           | 42.45                                       |
| <b>Total Income from Operations (Net)</b>                                               | <b>3135.73</b>                           | <b>2903.33</b>                           | <b>2539.25</b>                           | <b>2476.54</b>                           | <b>8578.31</b>                                  | <b>7574.86</b>                                  | <b>10040.76</b>                             |
| <b>EXPENSES:</b>                                                                        |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| Cost of Materials Consumed                                                              | 1299.25                                  | 1401.62                                  | 951.59                                   | 965.71                                   | 3652.46                                         | 2846.53                                         | 3287.68                                     |
| Purchase of Stock-in-Trade                                                              | 433.18                                   | 176.04                                   | 294.46                                   | 355.15                                   | 903.68                                          | 1151.71                                         | 1921.99                                     |
| Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade           | (325.58)                                 | 138.72                                   | 83.25                                    | (57.38)                                  | (103.61)                                        | (200.85)                                        | (107.75)                                    |
| Employee Benefits Expenses                                                              | 433.09                                   | 249.11                                   | 144.05                                   | 130.20                                   | 826.25                                          | 368.99                                          | 544.85                                      |
| Depreciation and Amortisation Expenses                                                  | 61.38                                    | 57.76                                    | 63.00                                    | 50.99                                    | 182.14                                          | 153.64                                          | 217.95                                      |
| Other Expenses                                                                          | 986.40                                   | 648.32                                   | 779.37                                   | 810.25                                   | 2414.09                                         | 2621.58                                         | 3278.98                                     |
| <b>Total Expenses</b>                                                                   | <b>2887.72</b>                           | <b>2671.57</b>                           | <b>2315.72</b>                           | <b>2254.92</b>                           | <b>7875.01</b>                                  | <b>6941.59</b>                                  | <b>9143.70</b>                              |
| <b>Profit from Operations before Other Income, finance costs and Exceptional Items</b>  | <b>248.01</b>                            | <b>231.76</b>                            | <b>223.53</b>                            | <b>221.62</b>                            | <b>703.30</b>                                   | <b>633.27</b>                                   | <b>897.06</b>                               |
| Other Income                                                                            | 7.72                                     | 6.10                                     | 1.12                                     | 3.13                                     | 14.94                                           | 3.76                                            | 12.25                                       |
| <b>Profit from ordinary activities before finance costs and exceptional items</b>       | <b>255.73</b>                            | <b>237.86</b>                            | <b>224.65</b>                            | <b>224.75</b>                            | <b>718.24</b>                                   | <b>637.03</b>                                   | <b>909.31</b>                               |
| Finance Costs                                                                           | 100.16                                   | 87.30                                    | 102.08                                   | 94.25                                    | 289.54                                          | 235.58                                          | 383.00                                      |
| <b>Profit from ordinary activities after finance costs but before exceptional items</b> | <b>155.58</b>                            | <b>150.57</b>                            | <b>122.57</b>                            | <b>130.49</b>                            | <b>428.71</b>                                   | <b>401.44</b>                                   | <b>526.31</b>                               |
| Exceptional Items                                                                       | 0.00                                     | 0.00                                     | 0.00                                     | 0.00                                     | 0.00                                            | 0.00                                            | 0.00                                        |
| <b>Profit from Ordinary Activities Before Tax</b>                                       | <b>155.58</b>                            | <b>150.57</b>                            | <b>122.57</b>                            | <b>130.49</b>                            | <b>428.71</b>                                   | <b>401.44</b>                                   | <b>526.31</b>                               |
| Current Tax                                                                             | 42.50                                    | 23.57                                    | 43.00                                    | 45.40                                    | 109.07                                          | 139.90                                          | 149.50                                      |
| Deferred Tax                                                                            | 6.45                                     | 12.26                                    | 0.00                                     | 0.00                                     | 18.71                                           | 0.00                                            | 53.19                                       |
| Short/(Excess) Tax Provisions of Earlier Years                                          | 0.00                                     | 0.00                                     | 0.00                                     | 0.00                                     | 0.00                                            | 0.00                                            | (9.30)                                      |
| <b>Net Profit from Ordinary Activities After Tax</b>                                    | <b>106.63</b>                            | <b>114.74</b>                            | <b>79.57</b>                             | <b>85.09</b>                             | <b>300.93</b>                                   | <b>261.54</b>                                   | <b>332.92</b>                               |
| Extraordinary Items (Net of Tax Expenses)                                               | 0.00                                     | 0.00                                     | 0.00                                     | 0.00                                     | 0.00                                            | 0.00                                            | 0.00                                        |
| <b>Net Profit for the Period</b>                                                        | <b>106.63</b>                            | <b>114.74</b>                            | <b>79.57</b>                             | <b>85.09</b>                             | <b>300.93</b>                                   | <b>261.54</b>                                   | <b>332.92</b>                               |
| Paid up Equity Share Capital (Face Value of Rs 1 /- Each)                               | 773.50                                   | 773.50                                   | 773.50                                   | 773.50                                   | 773.50                                          | 773.50                                          | 773.50                                      |
| Reserves Excluding Revaluation Reserves                                                 | 1766.82                                  | 1660.19                                  | 1545.46                                  | 1439.46                                  | 1766.82                                         | 1439.46                                         | 1465.89                                     |
| <b>E.P.S</b>                                                                            | <b>0.14</b>                              | <b>0.15</b>                              | <b>0.10</b>                              | <b>0.11</b>                              | <b>0.39</b>                                     | <b>0.34</b>                                     | <b>0.43</b>                                 |
| <b>Public Shareholding</b>                                                              |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| - Number of Shares of Rs 1 /- Each                                                      | 23222355                                 | 23222355                                 | 23222355                                 | 23222355                                 | 23222355                                        | 23222355                                        | 23222355                                    |
| - Percentage of shareholding                                                            | 30.02%                                   | 30.02%                                   | 30.02%                                   | 30.02%                                   | 30.02%                                          | 30.02%                                          | 30.02%                                      |
| <b>Promoters and Promoter group Shareholding</b>                                        |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| <b>a) Pledged / Encumbered</b>                                                          |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| - Number of Shares of Rs 1 /- Each                                                      | 0                                        | 0                                        | 0                                        | 0                                        | 0                                               | 0                                               | 0                                           |
| - Percentage of Shares the total Shareholding of Promoter and Promoter group            | 0.00%                                    | 0.00%                                    | 0.00%                                    | 0.00%                                    | 0.00%                                           | 0.00%                                           | 0.00%                                       |
| - Percentage of Shareholding on total Capital of the company                            | 0.00%                                    | 0.00%                                    | 0.00%                                    | 0.00%                                    | 0.00%                                           | 0.00%                                           | 0.00%                                       |
| <b>b) Non - Encumbered</b>                                                              |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| - Number of Shares of Rs 1 /- Each                                                      | 54127645                                 | 54127645                                 | 54127645                                 | 54127645                                 | 54127645                                        | 54127645                                        | 54127645                                    |
| - Percentage of Shares the total Shareholding of Promoter and Promoter group            | 100.00%                                  | 100.00%                                  | 100.00%                                  | 100.00%                                  | 100.00%                                         | 100.00%                                         | 100.00%                                     |
| - Percentage of Shareholding on total Capital of the company                            | 69.98%                                   | 69.98%                                   | 69.98%                                   | 69.98%                                   | 69.98%                                          | 69.98%                                          | 69.98%                                      |

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 15th February, 2014 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

For GUFIC BIOSCIENCES LTD.

 Praveen J. Choksi  
Executive Director

 Place: Mumbai  
Date: 15.02.2014

**GUFIC BIOSCIENCES LIMITED**

Regd office : 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai-400 069

**UNAUDITED SEGMENT WISE RESULTS FOR THE QUARTER ENDED 31.12.2013****Rs in Lacs**

| Particulars                  | Quarter Ended<br>31.12.2013<br>Unaudited | Quarter Ended<br>30.09.2013<br>Unaudited | Quarter Ended<br>30.06.2013<br>Unaudited | Quarter Ended<br>31.12.2012<br>Unaudited | For the Period Ended<br>31.12.2013<br>Unaudited | For the Period Ended<br>31.12.2012<br>Unaudited | For the Year Ended<br>31.03.2013<br>Audited |
|------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------|
| <b>SEGMENT REVENUE</b>       |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| <b>Sales &amp; Service</b>   |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| Pharma                       | 2822.90                                  | 2551.98                                  | 2291.38                                  | 2239.04                                  | 7666.26                                         | 6803.26                                         | 9085.06                                     |
| Consumer                     | 307.99                                   | 349.46                                   | 245.54                                   | 222.73                                   | 902.99                                          | 742.83                                          | 913.25                                      |
| <b>Total</b>                 | <b>3130.89</b>                           | <b>2901.44</b>                           | <b>2536.92</b>                           | <b>2461.77</b>                           | <b>8569.25</b>                                  | <b>7546.09</b>                                  | <b>9998.31</b>                              |
| Unallocated Income           | 12.56                                    | 7.99                                     | 3.45                                     | 17.90                                    | 24.00                                           | 32.53                                           | 54.70                                       |
| <b>Total Segment Revenue</b> | <b>3143.45</b>                           | <b>2909.43</b>                           | <b>2540.37</b>                           | <b>2479.67</b>                           | <b>8593.25</b>                                  | <b>7578.62</b>                                  | <b>10053.01</b>                             |
| <b>SEGMENT RESULTS</b>       |                                          |                                          |                                          |                                          |                                                 |                                                 |                                             |
| Pharma                       | 545.15                                   | 493.88                                   | 445.20                                   | 434.13                                   | 1484.23                                         | 1319.09                                         | 1761.51                                     |
| Consumer                     | 60.59                                    | 67.25                                    | 47.85                                    | 43.08                                    | 175.69                                          | 143.69                                          | 176.66                                      |
| <b>TOTAL</b>                 | <b>605.74</b>                            | <b>561.13</b>                            | <b>493.05</b>                            | <b>477.21</b>                            | <b>1659.92</b>                                  | <b>1462.78</b>                                  | <b>1938.17</b>                              |
| Less: Unallocated over heads | 288.63                                   | 265.51                                   | 205.40                                   | 201.47                                   | 759.54                                          | 672.12                                          | 810.91                                      |
| Finance Charges              | 100.16                                   | 87.30                                    | 102.08                                   | 94.25                                    | 289.54                                          | 235.58                                          | 383.00                                      |
| Depreciation                 | 61.38                                    | 57.76                                    | 63.00                                    | 50.99                                    | 182.14                                          | 153.64                                          | 217.95                                      |
| Tax provision                | 48.95                                    | 35.83                                    | 43.00                                    | 45.40                                    | 127.78                                          | 139.90                                          | 193.39                                      |
| <b>Net Profit after Tax</b>  | <b>106.63</b>                            | <b>114.74</b>                            | <b>79.57</b>                             | <b>85.09</b>                             | <b>300.93</b>                                   | <b>261.54</b>                                   | <b>332.92</b>                               |

The above Results were reviewed by the Audit Committee and taken on record by the Board of Directors at its meeting held on 15th February, 2014 and a limited review of the same has been carried out by the Statutory Auditors of the Company.

Investors Complaints received and disposed off during the Quarter Ended 31st December, 2013.

Complaints Pending at the Beginning of the quarter  
Complaints received during the quarter  
Disposal of Complaints  
Complaints lying unresolved at the end of the quarter

**Nos**

Nil  
7  
7  
Nil

Previous periods' figures have been regrouped, rearranged, reworked or reclassified wherever necessary to confirm to the current periods' classification

For GUFIC BIOSCIENCES LTD.

*Pranav J. Choksi*  
Pranav J. Choksi  
Executive Director

Date: 15.02.2014

Place: Mumbai